
Objectives: The study aims to investigate the risk of consanguineous unions and female infertility, along with the reproductive trends within such families. The effects of consanguinity on reproduction have been well documented; its involvement in female infertility and other aspects of family dynamics remains under-explored. Material and Methods: The present study employs a case-control design to compare the risk of consanguineous union in the proband and the familial history of infertile females (cases, N=191) with fertile females (controls, N=101), whereby odds ratios (OR) are calculated using logistic regression analysis. Results: In this study, the frequency of consanguineous union among infertile females was higher than that of the control females (<0.05). The infertile females also had a higher percentage of parents in consanguineous marriages (10.5%) than controls (3%) ( p =0.034). Comparatively, the percentage of the proband paternal line consanguineous unions is less than the maternal-line consanguinity. This study also observed a significant ( p <0.05) difference in the proband sibling infertility and spontaneous abortions. Conclusion: Family-based molecular analysis is needed for investigating the genetic causes of clustered female infertility within families, which may be helpful in elucidating specific genetic causes and their inheritance pattern.
Objectives: The primary aim of this study was to compare the serum follicle stimulating hormone (FSH) on stimulation day 5 or 6 when patients are stimulated with recombinant FSH (rFSH) or human menopausal gonadotropin (HMG). The secondary objective was to compare the absolute rise in serum FSH from baseline to day 5/6 of stimulation [delta FSH] between the two drugs. Material and Methods: Controlled ovarian hyperstimulation was started on the second or third day of the menstrual cycle with rFSH or HMG as per the clinician’s judgement. Patients took injections in the evening between 8–10 pm, and blood collection for serum FSH measurement was done in the morning of the day of stimulation start (baseline FSH) and again on day 5 or 6 [Day 5/6 FSH] of stimulation. Data was collected from the software Vrepro and patients’ medical records. Results: Initial analysis included 272 patients (204 in the HMG group and 68 in the rFSH group), with significant imbalances in gonadotropin dosing. After propensity score matching of 68 patients in each group, baseline characteristics (age, BMI, protocol distribution, gonadotropin doses) were well balanced between the groups. Despite similar baseline FSH levels (7.0 vs. 7.0 IU/L; p = 0.836), patients receiving rFSH achieved significantly higher day 5/6 FSH levels compared to those receiving HMG (19.6 vs. 15.5 IU/L; p <0.001), with a correspondingly higher absolute FSH increase (12.6 vs. 7.6 IU/L; p <0.001) and percentage increase (180.4 vs. 118.2%; p <0.001) Conclusion: Our analysis demonstrates that serum FSH level on day 5/6 of IVF stimulation is significantly higher when patients are stimulated with rFSH than HMG, with a correspondingly higher absolute increase from baseline.
Infertility is the inability of a sexually active couple to conceive within 1 year. It affects 10-15% of couples globally, with male factors accounting for 40-50% of these cases. The decline in semen quality, often with unknown causes, emphasises the need to evaluate sperm count, motility, and morphology when assessing male reproductive health. Environmental, occupational, and lifestyle factors are increasingly recognised as important contributors to male infertility, often linked to oxidative stress and disruptions in spermatogenesis. Exposure to pesticides, such as organochlorines and organophosphates, is associated with lower sperm count, poor motility, testicular issues, and negative reproductive outcomes in offspring. Similarly, exposure to metals like lead may harm spermatogenesis and raise the chances of low birth weight and prematurity. Diets high in ultra-processed foods (UPFs) have been associated with increased oxidative stress, cause inflammation, and limit essential nutrients needed for sperm quality, contributing to infertility. Psychosocial and occupational stress, along with heat exposure and electromagnetic radiation, further hinder sperm function by disrupting hormonal balance, increasing reactive oxygen species (ROS) formation, and causing apoptosis in testicular cells. Together, these factors illustrate the complex interactions among chemical, physical, nutritional, and psychosocial influences on male reproductive health. Reducing these risks may be important for maintaining male reproductive health through safe work practices, dietary changes, stress management, and environmental awareness is vital for maintaining fertility. Understanding how these exposures impact spermatogenesis and sperm quality can guide public health initiatives, workplace safety rules, and lifestyle changes aimed at enhancing male reproductive health. While oxidative stress-mediated sperm dysfunction is supported by substantial clinical and experimental evidence, data regarding epigenetic alterations, microplastics, occupational stress interactions, and dietary influences represent emerging areas of investigation and require further validation. This manuscript is a narrative review article. We did not conduct any original observational or experimental study. No primary data collection, participant recruitment, or laboratory analysis was performed. All evidence discussed is derived from previously published peer-reviewed in vitro studies.
Objectives: To study reproductive outcomes in different polycystic ovary syndrome (PCOS) phenotypes after in vitro fertilisation (IVF) treatments. Material and Methods: It is a prospective observational study, conducted from October 2024 to April 2025 at the Centre of IVF and Human Reproduction, Sir Ganga Ram Hospital, New Delhi. Women undergoing IVF were screened for the presence of PCOS and diagnosed based on Rotterdam’s criteria. These women were then subcategorised into the four PCOS phenotypes based on their presenting features. All women with PCOS who were scheduled for assisted reproductive technologies (ART) procedures during the study period and met the inclusion criteria were enrolled in the study. Metabolic disorders were screened with lipid profiles, mean blood glucose levels, and free androgen index. Primary outcomes studied were the β hCG positive rate, implantation rate per transfer, clinical pregnancy rates after the first transfer, and early pregnancy loss rate. Secondary outcomes studied were total dose of gonadotropins used, days of stimulation, number of oocytes retrieved, number of oocytes fertilised, number of cleaved embryos, fertilisation rate, median utilisable blastocyst number per patient, blastulation rate, and utilisable blastocyst rate. Results: There were 10 (18.9%) patients with phenotype A, 6 patients in phenotype B (11.3%), 15 in phenotype C (28.3%), and 22 in phenotype D (41.5%). The most prevalent phenotype was D (41.5%). Women with phenotype A though, had higher serum AMH levels ( p -value = 0.006), and had a higher median utilisable blastocyst number per patient ( p value = 0.024), but the β-hCG positive rate, implantation rates after first embryo transfer, clinical pregnancy rate, and early pregnancy loss rate were similar in the patients with different phenotypes of PCOS. There was no statistical difference in the total dose of gonadotropins used, number of oocytes retrieved, oocytes fertilised, cleaved embryos, fertilisation rate, blastulation rate, and utilisable blastocyst rate. Metabolic disorder screening results indicated higher cholesterol levels in patients with Phenotype B ( p value = 0.01), although no difference was noted in levels of HDL, LDL, non-HDL, triglycerides, and mean glucose levels in the patients with different phenotypes of PCOS. Conclusion: Our study results suggest that reproductive outcomes, including β hCG positive rate, implantation rate per embryo transfer, clinical pregnancy rate after first embryo transfer, and early pregnancy loss rates, were similar amongst patients with different phenotypes of PCOS. Patients with phenotype A had higher serum AMH levels and had a higher median utilisable blastocyst number per patient, but the utilisable blastocyst rate was comparable across all the phenotypes of PCOS. The study is underpowered to detect differences in reproductive outcomes due to the smaller number of patients enrolled in the study.
Gestational diabetes mellitus (GDM) poses significant challenges in modern obstetrics, driving increased monitoring and intervention. Emerging evidence suggests that the embryo's exposure to maternal hyperglycaemia and the consequent hyperinsulinaemia, leading to epigenetic changes and accelerated foetal growth, occurs much earlier than the typical 24–28-week screening window. Early epigenetic changes are the determinants of future health. Current research, though, demonstrates a moderate maternal and foetal benefit in treating GDM; the available data are not supportive of the prevention of long-term cardiometabolic health risks in the offspring despite treatment in mid-trimester. Pre-pregnancy maternal body mass index (BMI) and excessive gestational weight gain are more potent predictors of higher birth weight and macrosomia than mid-trimester hyperglycaemia alone. While treating hyperglycaemia is essential, addressing pre-pregnancy maternal high BMI is equally important.